Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child–Turcotte–Pugh Class C Cirrhosis and Renal Dysfunction
KeywordsSildenafil Cirrhosis Pharmacokinetics Renal dysfunction
The authors thank Heather L. Rebuck, MT (ASCP), CLS (NCA), and Sharon Y. Huang, MT (Clinical Chemistry Research Lab, University of Maryland Baltimore), University of Maryland General Clinical Research Center Staff and Galina Bikzhanova, Ph.D. (Discovery Bioanalytical Chemistry, Covance Laboratories, Inc.) for their support.
Conflict of interest
Robert H. Christenson, Ph.D. reported that he is a consultant for Roche Diagnostics and Siemens Healthcare Diagnostics and have research contracts with both.
The project described was supported in part by Grant Number 5 K23 DK089008-05 from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (to Ayse L. Mindikoglu, M.D., M.P.H.), and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the NIH. This work was also supported by the University of Maryland School of Medicine, Department of Medicine funds (to Ayse L. Mindikoglu, M.D., M.P.H.), University of Maryland Clinical Translational Science Institute, and the University of Maryland General Clinical Research Center.
- 12.Revatio (sildenafil). http://labeling.pfizer.com/ShowLabeling.aspx?id=645. Accessed 19 Aug 2013.